|Study Description:||The goal of Part I of this clinical research study is to find the highest |
tolerable dose of TPI 287 that can be given with bevacizumab to patients with
glioblastoma. The goal of Part II is to learn if TPI 287 when given with
bevacizumab can help to control glioblastoma better than when bevacizumab is
given alone. The safety of the drug combination will also be studied.
TPI 287 is similar to a type of chemotherapy drug called a taxane and is
designed to block a protein (tubulin) that helps the cancer cells divide. By
blocking the tubulin, the drug may be able to cause the cancer cells to shrink
or stop growing.
Bevacizumab is designed to prevent or slow down the growth of cancer cells by
blocking the growth of blood vessels.